These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27193205)

  • 1. Early synaptic dysfunction in Parkinson's disease: Insights from animal models.
    Schirinzi T; Madeo G; Martella G; Maltese M; Picconi B; Calabresi P; Pisani A
    Mov Disord; 2016 Jun; 31(6):802-13. PubMed ID: 27193205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease.
    Imbriani P; Martella G; Bonsi P; Pisani A
    Neurobiol Dis; 2022 Oct; 173():105851. PubMed ID: 36007757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: Parkinson's disease: from synaptic loss to connectome dysfunction.
    Bellucci A; Mercuri NB; Venneri A; Faustini G; Longhena F; Pizzi M; Missale C; Spano P
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):77-94. PubMed ID: 26613567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of autophagy and vesicle trafficking in Parkinson's disease.
    Sheehan P; Yue Z
    Neurosci Lett; 2019 Apr; 697():59-65. PubMed ID: 29627340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic dysfunction in Parkinson's disease.
    Bagetta V; Ghiglieri V; Sgobio C; Calabresi P; Picconi B
    Biochem Soc Trans; 2010 Apr; 38(2):493-7. PubMed ID: 20298209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease: mechanisms and models.
    Dauer W; Przedborski S
    Neuron; 2003 Sep; 39(6):889-909. PubMed ID: 12971891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of mouse models of Parkinson's disease.
    Bobela W; Zheng L; Schneider BL
    Curr Protoc Mouse Biol; 2014 Sep; 4(3):121-39. PubMed ID: 25723963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising rodent models in Parkinson's disease.
    Imbriani P; Sciamanna G; Santoro M; Schirinzi T; Pisani A
    Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1():S10-S14. PubMed ID: 28760592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Axonal Degeneration a Key Early Event in Parkinson's Disease?
    Kurowska Z; Kordower JH; Stoessl AJ; Burke RE; Brundin P; Yue Z; Brady ST; Milbrandt J; Trapp BD; Sherer TB; Medicetty S
    J Parkinsons Dis; 2016 Oct; 6(4):703-707. PubMed ID: 27497486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons.
    Touchette JC; Breckenridge JM; Wilken GH; Macarthur H
    Neurosci Lett; 2016 Jan; 612():178-184. PubMed ID: 26704434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis.
    Licker V; Turck N; Kövari E; Burkhardt K; Côte M; Surini-Demiri M; Lobrinus JA; Sanchez JC; Burkhard PR
    Proteomics; 2014 Mar; 14(6):784-94. PubMed ID: 24449343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparagine endopeptidase cleaves synaptojanin 1 and triggers synaptic dysfunction in Parkinson's disease.
    Zou L; Zhang X; Xiong M; Meng L; Tian Y; Pan L; Yuan X; Chen G; Wang Z; Bu L; Yao Z; Zhang Z; Ye K; Zhang Z
    Neurobiol Dis; 2021 Jul; 154():105326. PubMed ID: 33677035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease.
    Grosch J; Winkler J; Kohl Z
    Front Cell Neurosci; 2016; 10():293. PubMed ID: 28066188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.